Search Videos and More
Document
Treatment Guideline: Ovarian Function Suppression and Estradiol Monitoring in Early-Stage Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of ovarian function suppression and estradiol monitoring in early-stage estrogen receptor positive breast cancer.
News
Dana-Farber Research News 11.01.2025
This twice-monthly newsletter highlights recently published research in which Dana-Farber faculty are listed as first or senior authors. The information is sourced from PubMed, and this issue covers papers published October 1-15.
Course
CME: ASH 2025 Highlights
Delivers disease-specific updates from the ASH Annual Meeting to equip hematologists, oncologists, and other clinicians with the knowledge to identify, understand, and apply emerging therapies in the treatment of blood cancers.
Document
Tip Sheet: Caring for Transgender and Gender Diverse Patients
The Breast Oncology Center developed this reference for providers caring for transgender and gender diverse patients in October 2025.
Document
Expert Review: Early Palliative Care as an Adjunct to Disease-Directed Care in Breast Cancer
The Breast Oncology Center developed this reference for providers based on a presentation by James A. Tulsky, MD, given on February 26, 2025.
News
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.
News
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.
News
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.
News
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.
News
Dana-Farber Research News 10.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - September 30.
Course
Dana-Farber Center for BRCA & Related Genes Scientific Symposium
Explore the latest advances in hereditary cancer research and care at the Dana-Farber Center for BRCA and Related Genes Scientific Symposium, designed for clinicians and researchers to deepen knowledge of detection, treatment, and ethical issues in BRCA-associated cancers across multiple tumor types.
News
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.